<DOC>
	<DOC>NCT00108095</DOC>
	<brief_summary>This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV</brief_summary>
	<brief_title>A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting</brief_title>
	<detailed_description>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW67969, When Administered With Intravenous Ondansetron Hydrochloride for the Prevention of Post-Operative Nausea and Vomiting (PONV) and Post-Discharge Nausea and Vomiting (PDNV) in Female Subjects With Known Risk Factors for PONV Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea and Vomiting</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Inclusion criteria: Females age 1855 Laparoscopic/laparotomic gynecological procedure of laparoscopic gallbladder removal Exclusion criteria: Pregnant or breastfeeding Postmenopausal Not undergoing general anesthesia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>emesis</keyword>
	<keyword>nausea</keyword>
	<keyword>post operative nausea and vomiting</keyword>
	<keyword>vomiting</keyword>
	<keyword>PONV</keyword>
</DOC>